Stockscreener 앱 받기
1.69
0.60%
0.01
Processa Pharmaceuticals Inc 주식(PCSA)의 최신 뉴스
Form PRE 14A Processa Pharmaceuticals Inc For: 9 October By Investing.com - Investing.com Canada
Processa Pharmaceuticals files prospectus for 306.574M share sale - scanx.trade
Processa Pharmaceuticals Proposes Reverse Stock Split Following Merger with Vidya Therapeutics - Kalkine Media
Selling stockholders would receive resale proceeds, with none going to Processa (Nasdaq: PCSA). - Stock Titan
Processa Pharmaceuticals Files Amended 8-K/A Including Financials for Vidya Therapeutics Acquisition - Kalkine Media
Processa Pharmaceuticals at H.C. Wainwright: bets on vt-7208 By Investing.com - Investing.com South Africa
Processa Pharmaceuticals at H.C. Wainwright: bets on vt-7208 By Investing.com - Investing.com Canada
Processa Pharmaceuticals at H.C. Wainwright: bets on vt-7208 By Investing.com - Investing.com UK
Processa Pharmaceuticals at wells fargo healthcare conference: cash fuels vt-7208 push - Investing.com Canada
Processa Pharmaceuticals at wells fargo healthcare conference: cash fuels vt-7208 push - Investing.com UK
Processa Pharmaceuticals Inc. (PCSA) Peer Comparison – Compare with Others - Value Research
Processa Pharmaceuticals Inc. (PCSA) Key Financial Ratios – Valuation, Profitability & More - Value Research
Processa Pharmaceuticals Inc. (PCSA) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
A doctor on Processa Pharmaceuticals' board will present at two investor conferences on Sept. 10 and 11. - Stock Titan
Processa Pharmaceuticals to Participate in Upcoming Investor Conferences - Yahoo Finance
Processa Pharmaceuticals Inc. (PCSA) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Processa (PCSA) Range: Closes 0.47% Lower at $2.14 in Latest Trading; Next Test: Support at $2.03 and Resistance at $2.25 Frame the RangeDark Pool Volume - vinanet.vn
Processa Pharmaceuticals (NASDAQ: PCSA) gains new 5.8% owner with no sole control - Stock Titan
Processa Pharmaceuticals (PCSA) Slips 12% as Biotech Volatility PersistsChaikin Flow - dars.gov.et
Processa Pharmaceuticals (PCSA) Slips 12% as Biotech Volatility PersistsLinear Regression - vinanet.vn
Processa Pharmaceuticals (PCSA) Slips 12% as Biotech Volatility PersistsDay Trade Opportunities - dars.gov.et
Processa Pharmaceuticals 3Q 2026: Net loss $(3.27M), EPS $(1.19) — 10-Q Summary - TradingView
Processa Pharmaceuticals (NASDAQ: PCSA) lands $183M funding and Vidya BTK acquisition - Stock Titan
Processa Pharmaceuticals shareholders approve incentive plan amendment at annual meeting - Investing.com Nigeria
Form 8K Processa Pharmaceuticals Inc For: 14 August By Investing.com - Investing.com Nigeria
Processa Pharmaceuticals shareholders approve incentive plan amendment at annual meeting - Investing.com
Processa Pharmaceuticals shareholders approve incentive plan amendment at annual meeting - Investing.com UK
Processa Pharmaceuticals shareholders approve incentive plan amendment at annual meeting - Investing.com
Form 8K Processa Pharmaceuticals Inc For: 14 August By Investing.com - Investing.com India
Processa Pharmaceuticals (PCSA) Slips 2.34% to $2.5 as Support at $2.38 Comes into FocusPercent Above MA - vinanet.vn
Processa Pharmaceuticals shareholders approve incentive plan amendment and board elections - Investing.com UK
Form 8K Processa Pharmaceuticals Inc For: 11 August By Investing.com - Investing.com Nigeria
Processa Pharmaceuticals shareholders approve incentive plan amendment and board elections - Investing.com Nigeria
Processa Pharmaceuticals shareholders approve incentive plan amendment and board elections - Investing.com
Form 8K Processa Pharmaceuticals Inc For: 11 August By Investing.com - Investing.com Canada
Processa Pharmaceuticals shareholders approve incentive plan amendment and board elections - Investing.com
Processa Pharmaceuticals Inc (PCSA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Processa Pharmaceuticals (PCSA) Surges 11.74% to $2.57 — Poised for a Test of $2.70 ResistanceQuality Factor - vinanet.vn
Processa Pharmaceuticals Inc (PCSA) Stock News Today - TradingKey
Processa Pharmaceuticals Inc (PCSA) Earnings, Actual EPS, EPS Estimates & Results - stocktwits.com
Processa Pharmaceuticals Inc (NASDAQ: PCSA) Share Price, PCSA Stock News, PCSA Share Price & Updates - Kalkine
Processa Pharmaceuticals, Inc. 8-K SEC Filing Details – Nasdaq Listed Company Information (July 30, 2026) - Minichart
Processa Pharmaceuticals Shareholders Approve Key Governance Changes - TipRanks
Processa Pharmaceuticals (NASDAQ: PCSA) adds 200,000 incentive shares - Stock Titan
Mintz Advises on $200 Million Private Placement Concurrent with Vidya Therapeutics’ and Processa Pharmaceuticals’ Merger Transaction - Mintz
Form 4 Processa Pharmaceuticals Inc For: 30 July By Investing.com - Investing.com Nigeria
Processa acquires Vidya and its BTK inhibitor - The Pharma Letter
Processa Pharmaceuticals, Inc. announced that it expects to receive $200 million in funding from a group of investors - marketscreener.com
Processa Merges With Vidya and Secures $200 Million PIPE; Terminates Elion License - TradingView
PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEMENT TO ADVANCE BTK INHIBITOR, VT-7208, IN MULTIPLE DISEASE AREA - GlobeNewswire
4.22%
자본화:
|
볼륨(24시간):